Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen s Q1 Revenues Up 10 Percent, Earnings Quadruple Thanks to Dynal Purchase

NEW YORK, April 29 (GenomeWeb News) - Invitrogen yesterday reported a 10-percent increase in revenues and quadrupled earnings for the first quarter of 2005.

 

Revenues for the quarter totaled $277.1 million, up from $251.3 million during the year-ago period. Both Invitrogen's BioDiscovery and BioProduction segments contributed to this increase.

 

Research and development expenses increased to $21.2 million from $15.7 million during the first quarter of 2004.

 

The company's net income increased to $47.1 million, or $.82 per share, from $10.5 million, or $.19 per share, during last year's first quarter. Included in this quarter's income is a gain of $21 million related to the hedging activity associated with Invitrogen's acquisition of Dynal.

 

As of March 31, Invitrogen had $1 billion in cash and investments.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.